MA26845A1 - CRYSTALLINE FORM OF 4-CARBOXYAMINO-2-ETHYL-1,2,3,4- - Google Patents
CRYSTALLINE FORM OF 4-CARBOXYAMINO-2-ETHYL-1,2,3,4-Info
- Publication number
- MA26845A1 MA26845A1 MA26653A MA26653A MA26845A1 MA 26845 A1 MA26845 A1 MA 26845A1 MA 26653 A MA26653 A MA 26653A MA 26653 A MA26653 A MA 26653A MA 26845 A1 MA26845 A1 MA 26845A1
- Authority
- MA
- Morocco
- Prior art keywords
- carboxyamino
- ethyl
- crystalline form
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16805199P | 1999-11-30 | 1999-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA26845A1 true MA26845A1 (en) | 2004-12-20 |
Family
ID=22609901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA26653A MA26845A1 (en) | 1999-11-30 | 2002-05-27 | CRYSTALLINE FORM OF 4-CARBOXYAMINO-2-ETHYL-1,2,3,4- |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1246804A1 (en) |
JP (1) | JP2003515592A (en) |
KR (1) | KR20020058057A (en) |
CN (1) | CN1402711A (en) |
AP (1) | AP2002002531A0 (en) |
AU (1) | AU1048801A (en) |
BG (1) | BG106854A (en) |
BR (1) | BR0015836A (en) |
CA (1) | CA2392979A1 (en) |
CO (1) | CO5271716A1 (en) |
EA (1) | EA200200510A1 (en) |
EC (1) | ECSP003792A (en) |
EE (1) | EE200200277A (en) |
GT (1) | GT200000199A (en) |
HU (1) | HUP0203521A2 (en) |
IL (1) | IL149097A0 (en) |
IS (1) | IS6338A (en) |
MA (1) | MA26845A1 (en) |
MX (1) | MXPA02005354A (en) |
NO (1) | NO20022558L (en) |
OA (1) | OA12099A (en) |
PA (1) | PA8506301A1 (en) |
PE (1) | PE20010904A1 (en) |
PL (1) | PL355892A1 (en) |
TN (1) | TNSN00231A1 (en) |
TR (1) | TR200201446T2 (en) |
UY (1) | UY26454A1 (en) |
WO (1) | WO2001040190A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
TNSN03139A1 (en) | 2001-06-21 | 2005-12-23 | Pfizer Prod Inc | SELF-EMULSIBLE FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS |
GT200200170A (en) | 2001-09-28 | 2003-05-23 | PREPARATION OF INHIBITOR OF CETP ANHIDRO | |
PT1469833T (en) * | 2002-02-01 | 2021-07-13 | Bend Res Inc | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
EP1920766B1 (en) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
ATE395044T1 (en) | 2002-02-01 | 2008-05-15 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS OF AMORPHIC DISPERSIONS OF ACTIVE INGREDIENTS AND LIPOPHILIC MICROPHASE-FORMING MATERIALS |
ES2277142T3 (en) | 2002-08-30 | 2007-07-01 | Japan Tobacco Inc. | DIBENCILAMINE COMPOSITE AND ITS MEDICINAL USE. |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US7211672B2 (en) | 2002-10-04 | 2007-05-01 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
BR0317521A (en) | 2002-12-20 | 2005-11-16 | Pfizer Prod Inc | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
JP2006521344A (en) * | 2003-03-28 | 2006-09-21 | ファイザー・プロダクツ・インク | 1,2,4-substituted 1,2,3,4-tetrahydro- and 1,2-dihydro-quinoline and 1,2,3,4 as CETP inhibitors for the treatment of atherosclerosis and obesity -Tetrahydro-quinoxaline derivatives |
JP2007501218A (en) | 2003-08-04 | 2007-01-25 | ファイザー・プロダクツ・インク | Pharmaceutical composition of adsorbate of amorphous drug and lipophilic microphase-forming substance |
DK1670768T3 (en) | 2003-10-08 | 2009-11-09 | Lilly Co Eli | Compounds and Methods to Treat Dyslipidemia |
JP4922924B2 (en) * | 2004-04-13 | 2012-04-25 | メルク・シャープ・エンド・ドーム・コーポレイション | CETP inhibitor |
EP1761521A1 (en) * | 2004-06-24 | 2007-03-14 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
WO2006033004A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds as cetp inhibitors |
WO2006091674A1 (en) | 2005-02-24 | 2006-08-31 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
WO2006098394A1 (en) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | Method for inhibiting lipid absorption and lipid absorption inhibitor |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
AR065670A1 (en) | 2007-03-09 | 2009-06-24 | Indigene Pharmaceuticals Inc | COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTIHIPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
TWI450896B (en) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid |
MX2017000582A (en) | 2014-07-30 | 2017-04-27 | Hoffmann La Roche | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent. |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
WO1998033775A1 (en) * | 1997-02-03 | 1998-08-06 | American Home Products Corporation | 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
-
2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/en unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/en unknown
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/en not_active Application Discontinuation
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/en unknown
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/en active Pending
- 2000-11-14 EP EP00971662A patent/EP1246804A1/en not_active Withdrawn
- 2000-11-14 CN CN00816463A patent/CN1402711A/en active Pending
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/en unknown
- 2000-11-14 PL PL00355892A patent/PL355892A1/en not_active Application Discontinuation
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/en not_active IP Right Cessation
- 2000-11-14 CA CA002392979A patent/CA2392979A1/en not_active Abandoned
- 2000-11-14 EA EA200200510A patent/EA200200510A1/en unknown
- 2000-11-14 EE EEP200200277A patent/EE200200277A/en unknown
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/en not_active Application Discontinuation
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/en unknown
- 2000-11-14 IL IL14909700A patent/IL149097A0/en unknown
- 2000-11-28 UY UY26454A patent/UY26454A1/en not_active Application Discontinuation
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/en not_active Application Discontinuation
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/en unknown
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/en unknown
- 2000-11-29 GT GT200000199A patent/GT200000199A/en unknown
-
2002
- 2002-04-12 IS IS6338A patent/IS6338A/en unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/en unknown
- 2002-05-29 NO NO20022558A patent/NO20022558L/en not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1246804A1 (en) | 2002-10-09 |
EA200200510A1 (en) | 2002-10-31 |
AP2002002531A0 (en) | 2002-06-30 |
JP2003515592A (en) | 2003-05-07 |
CO5271716A1 (en) | 2003-04-30 |
IL149097A0 (en) | 2002-11-10 |
CN1402711A (en) | 2003-03-12 |
AU1048801A (en) | 2001-06-12 |
KR20020058057A (en) | 2002-07-12 |
CA2392979A1 (en) | 2001-06-07 |
WO2001040190A1 (en) | 2001-06-07 |
PL355892A1 (en) | 2004-05-31 |
TR200201446T2 (en) | 2002-11-21 |
MXPA02005354A (en) | 2002-12-11 |
UY26454A1 (en) | 2001-07-31 |
PA8506301A1 (en) | 2002-08-26 |
GT200000199A (en) | 2002-05-23 |
EE200200277A (en) | 2003-10-15 |
TNSN00231A1 (en) | 2002-05-30 |
HUP0203521A2 (en) | 2003-02-28 |
OA12099A (en) | 2006-05-04 |
BG106854A (en) | 2002-12-29 |
ECSP003792A (en) | 2002-04-23 |
NO20022558D0 (en) | 2002-05-29 |
IS6338A (en) | 2002-04-12 |
NO20022558L (en) | 2002-05-29 |
BR0015836A (en) | 2002-08-06 |
PE20010904A1 (en) | 2001-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA26845A1 (en) | CRYSTALLINE FORM OF 4-CARBOXYAMINO-2-ETHYL-1,2,3,4- | |
MA27349A1 (en) | CRYSTALLINE COMPOSITION CONTAINING ESCITALOPRAM. | |
DZ2817A1 (en) | Polymorphic form of clopidogrel hydrogen sulfate. | |
ID26743A (en) | DURING 1,2,4,5-TETRAHIDRO-BENZO [D] AZEPIN | |
NO20012857D0 (en) | Controlled release galantamine composition | |
PL380733A1 (en) | New derivatives of 3,3-diphenylpropylamines | |
DE69933287D1 (en) | 12,13-MODIFIED EPOTHILON DERIVATIVES | |
DE69907162D1 (en) | ORGANOPHILE PHYLLOSILICATES | |
HUP0204034A3 (en) | Stable salts of novel derivatives of 3,3-diphenylpropylamines | |
MA26500A1 (en) | NEW FORM OF S-OMERPRAZOLE | |
ID26310A (en) | PRODUCTION OF CONTINUED-1,3-DIOXOL-2-ONA | |
DE69920730D1 (en) | AQUEOUS COMPOSITION | |
ID29149A (en) | ADJUVAN COMPOSITION | |
AR027907A1 (en) | COMPOSITION OF CONTROLLED RELEASE | |
DE69919255D1 (en) | The engraver | |
IL137518A0 (en) | Derivatives of 1,2,4-oxadiazolone | |
DE60025958D1 (en) | 14,15-BETA-METHYLENE SUBSTITUTED ANDROGENE | |
AR028607A1 (en) | DERIVATIVES OF 1,4-DIAZEPAN-2,5-DIONA | |
ID22456A (en) | PROCESS OF MAKING DIESTER-DIESTER 2,3,5-TRIMETHYL HYDROXININON | |
ID27686A (en) | TURUNAN 3- (2-OKSO- [1,3] BIPIROLIDINIL-3-ILDENAMETIL) -SEFEM | |
DE69907161D1 (en) | 5 'DEOXYCYTIDINE DERIVATIVES | |
DE69917392D1 (en) | Crystalline polymer composition | |
NO20015397L (en) | 1,5-Benzodiazepine derivatives | |
DE59907066D1 (en) | blanket | |
ITMI992457A0 (en) | PROCEDURE FOR THE PREPARATION OF (S)-N-TERBUTYL-1,2,3,4-TETRAHYDROIS OCHINOLIN-3-CARBOXYAMIDE |